Women's Health Initiative Hormone Therapy Trials: New Insights on Cardiovascular Disease from Additional Years of Follow up

Current Cardiovascular Risk Reports

Volumn 7, Issue 3, 2013, Pages 196-202

  Miller, Virginia M ^a   Manson, JoAnn E ^b  

^a MAYO CLINIC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Conjugated equine estrogens; Medroxyprogesterone acetate; Myocardial infarction; Stroke; Timing hypothesis

Indexed keywords

26 HYDROXYCHOLESTEROL; ADIPOCYTOKINE; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; D DIMER; ESTRADIOL; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MEDROXYPROGESTERONE ACETATE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VON WILLEBRAND FACTOR;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIFICATION; DISEASE ASSOCIATION; FOLLOW UP; GENOTYPE; HEART INFARCTION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; MENOPAUSE; OUTCOME ASSESSMENT; OVARIECTOMY; PATIENT DECISION MAKING; PERSONALIZED MEDICINE; PHYSICIAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULAR DISEASE; WOMEN'S HEALTH;

EID: 84877020162     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-013-0305-1     Document Type: Review

References (46)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125: e2-e220.
2. Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, et al. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program follow-up study. JAMA. 1983; 249: 903-6.
3. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study. Circulation. 1987; 75: 1102-9.
4. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA. 2003; 289: 2673-84.
5. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349: 523-34.
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33.
7. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-12.
8. Manson JE. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metabolism. 2013; 62 Suppl 1: S15-9.
9. Group TWsHIS. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials. 1998; 19: 61-109.
10. • LaCroix A, Chlebowski RT, Manson JE, Aragaki A, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011; 305: 1305-14. Provides evidence for effect modification by age, which became stronger for some outcomes with inclusion of post-intervention follow up, and suggests a potential role for age in risk stratification.
11. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008; 299: 1036-45.
12. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein KP. Remodeling of coronary arteries in human and nonhuman primates. J Am Med Assoc. 1994; 271: 289-94.
13. Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2009; 2: 228-39.
14. Hodis HN, Bauer HJ, Rawlins DB, Mack WJ. A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age and time dependent. Brain Res. 2011; 1379: 244-52.
15. Rossouw J, Prentice R, Manson J, Wu L, Barad D, Barnabei V, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297: 1465.
16. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med. 2006; 166: 357-65.
17. Manson J, Allison M, Rossouw JE, Carr J, Langer R, Hsia J, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356: 2591-602.
18. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 2008; 14: 111-6.
19. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown Jr RD. Premature menopause or early menopause and risk of ischemic stroke. Menopause. 2012; 19: 272-7.
20. D'Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117: 743-53.
21. Bray PF, Larson JC, Lacroix AZ, Manson J, Limacher MC, Rossouw JE, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol. 2008; 101: 1599-605.
22. •• Huang G, Wang D, Zeb I, Budoff MJ, Harman SM, Miller V, et al. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis. 2012; 221: 198-205. Unique assessment of various fat depots and their relationship to coronary arterial calcification.
23. Rossouw JE, Prentice RL, Manson JE, Aragaki AK, Hsia J, Martin LW, et al. Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy. Circulation. 2012; 126: 1577-86.
24. •• Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause. 2013; 20(3): 254-60. Provides evidence that the constellation of clinical characteristics defining metabolic syndrome can help establish risk for use of menopausal hormone therapy. Although these data are derived from women on average ten years past menopause, the findings suggest that metabolic syndrome phenotype may be useful in stratifying women's coronary risk on MHT.
25. Jayachandran M, Litwiller RD, Lahr BD, Bailey KR, Owen WG, Mulvagh SL, et al. Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res. 2011; 4: 811-22.
26. Rossouw JE, Cushman M, Greenland P, Lloyd-Jones DM, Bray P, Kooperberg C, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med. 2008; 168: 2245-53.
27. Huang G, Wang D, Khan UI, Zeb I, Manson JE, Miller V, et al. Associations between retinol-binding protein 4 and cardiometabolic risk factors and subclinical atherosclerosis in recently postmenopausal women: cross-sectional analyses from the KEEPS Study. Cardiovasc Diabetol. 2012; 11(1): 52.
28. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007; 21: 157-71.
29. •• Jayachandran M, Miller VM, Heit JA, Owen WG. Methodology for isolation, identification and characterization of microvesicles in peripheral blood. J Immunol Methods. 2012; 375: 207-14. Provides methodological parameters for isolation and characterization of blood borne cell membrane-derived micorvesicles that if applied would help to standardize and enable analysis of microvesicles among studies.
30. Jayachandran M, Litwiller RD, Owen WG, Miller VM. Circulating microparticles and endogenous estrogen in newly menopausal women. Climacteric. 2009; 12: 177-84.
31. Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck TR, Mulvagh SL, et al. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol. 2008; 295: 931-8.
32. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004; 292: 1573-80.
33. Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C, et al. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol. 2011; 31: 464-9.
34. Miller VM, Petterson TM, Jeavons EN, Lnu AS, Rider DN, Heit JA, et al. Genetic polymorphisms associated carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiol Genomics. 2013; 45(2): 79-88. doi: 10. 1152/physiolgenomics. 00114. 2012. 34.
35. Crandall CJ, Crawford SL, Gold EB. Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am J Med. 2006; 119: S52-60.
36. Sowers MR, Wilson AL, Karvonen-Gutierrez CA, Kardia. Sex steroid hormone pathway genes and health-related measures in women of 4 races/ethnicities: the Study of Women's Health Across the Nation (SWAN). Am J Med. 2006; 119: S103-10.
37. Lo JC, Zhao X, Scuteri A, Brockwell S, Sowers MR. The association of genetic polymorphisms in sex hormone biosynthesis and action with insulin sensitivity and diabetes mellitus in women at midlife. Am J Med. 2006; 119: S69-78.
38. Sowers MR, Symons JP, Jannausch ML, Chu J, Kardia SR. Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women's Health Across the Nation (SWAN). Am J Med. 2006; 119: S61-8.
39. Sowers MR, Wilson AL, Kardia SR, Chu J, McConnell DS. CYP1A1 and CYP1B1 polymorphisms and their association with estradiol and estrogen metabolites in women who are premenopausal and perimenopausal. Am J Med. 2006; 119: S44-51.
40. Sowers MR, Jannausch ML, McConnell DS, Kardia SR, Randolph Jr JF. Endogenous estradiol and its association with estrogen receptor gene polymorphisms. Am J Med. 2006; 119: S16-22.
41. Rexrode KM, Manson JE. Are some types of hormone therapy safer than others? Lessons from the Estrogen and Thromboembolism Risk study. Circulation. 2007; 115: 820-2.
42. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 362: 428-32.
43. Lacut K, Oger E, Le Gal G, Blouch M-T, Abgrall J-F, Kerlan V, et al. Investigators atS differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost. 2003; 90: 124-31.
44. Ho JY-P, Chen M-J, Sheu WH-H, Yi Y-C, Tsai AC-W, Guu H-F, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod. 2006; 21: 2715-20.
45. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115: 840-5.
46. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2012; 19: 257-71.